Biotechnology

Tracon Pharma

TRACON Pharmaceuticals Announces Ceasing Operations

TRACON Pharmaceuticals terminates ENVASARC trial

TRACON Pharma quarterly earnings report release

Tracon Pharma released FY2022 Q2 earnings on August 10 After-Market (EST), actual revenue 0 (forecast 0), actual EPS -6.1475 (forecast -7.15)

EKSO Bionics

Profusa

Antelope Enterprise

Cemtrex

FLY-E

Borealis Foods

Zhongchao

ON24

374Water

Jyong Biotech

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

阿里拉姆制药

Argenx

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap